1. A method for scrolling within a Graphical User Interface (GUI) that includes a window with a field having a plurality of predetermined areas surrounded by a window frame separate from the field, said separate window frame including a vertical scroll bar having a vertical scroll tab and a horizontal scroll bar having a horizontal scroll tab, the method comprising:
in a cursor control mode, moving a cursor within the GUI in response to positional data received from a cursor control device, wherein the movement of the cursor within the GUI is directly based on the positional data and the cursor does not move when the there is no change in the received positional data;
receiving a clicking action from a button of the cursor control device in response to a user of the GUI clicking the button, the clicking action comprising a button press event and a button release event;
entering a scroll control mode in response to the received clicking action, in response to determining that the clicking action was received when the cursor was positioned within one of the plurality of predetermined areas in the field, said plurality of predetermined areas including separate predetermined areas that are located proximate to the vertical scroll tab, proximate to the horizontal scroll tab, and elsewhere within the field, wherein a vertical scroll control mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area proximate to the vertical scroll tab, a horizontal scroll control mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area proximate to the horizontal scroll tab, and a panning scroll mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area located elsewhere within the field;
wherein in the scroll control mode, scrolling of the contents of the window is directly based only on positional data received from the cursor control device in the direction of entered scroll control mode, and the contents of the window do not scroll when there is no change in the received positional data, whereby any time the positional data received from the cursor control device indicates no movement in the scroll control mode, the contents of the window do not scroll, and whereby if there is no horizontal change in the positional data received from the cursor control device when in horizontal scroll control mode, then the contents of the window do not scroll, and whereby if there is no vertical change in the positional data received from the cursor control device when in vertical scroll control mode, then the contents of the window do not scroll;
determining that a time period of inactivity has elapsed during which there was no activity by the cursor control device, such that no horizontal change and no vertical change in the received positional data and no clicking actions are received from the cursor control device during the inactive time period; and
returning to the cursor control mode from the scroll control mode in response to the determination that the time period of inactivity has elapsed, wherein in the cursor control mode the movement of the cursor within the GUI is directly based on the positional data and the cursor does not move when the there is no change in the received positional data.
2. The method of claim 1, wherein the cursor control device comprises a mouse, and wherein the positional data received from the mouse corresponds with movements of the mouse in relation to a surface upon with the mouse is in contact, such that the mouse is not being moved when there is no change in the received positional data.
3. The method of claim 2, wherein the received clicking action is performed using a primary button of the mouse.
4. The method of claim 3, wherein the primary button of the mouse is not dedicated to scrolling functionality.
5. The method of claim 1, wherein the cursor control device comprises a touch pad, and wherein the positional data received from the touch pad corresponds with movements of a user’s finger or stylus over the surface of the touch pad, such that the finger or stylus is not being moved when there is no change in the received positional data.
6. The method of claim 5, wherein the received clicking action is performed using a primary button associated with the touch pad.
7. The method of claim 6, wherein the primary button associated with the touch pad is not dedicated to scrolling functionality.
8. The method of claim 1, wherein the cursor control device comprises a trackball or a joystick.
9. The method of claim 1, further comprising changing an appearance of the scroll tab to indicate being in the scroll control mode in response to entering the scroll control mode.
10. The method of claim 1, further comprising:
receiving a second clicking action; and
returning to the cursor control mode from the scroll control mode in response to the received second clicking action, wherein in the cursor control mode the movement of the cursor within the GUI is directly based on the positional data and the cursor does not move when the there is no change in the received positional data.
11. The method of claim 10, further comprising changing the appearance of the scroll tab to indicate no longer being in the scroll control mode in response to returning to the cursor control mode.
12. The method of claim 9, further comprising changing the appearance of the scroll tab to indicate no longer being in the scroll control mode in response to returning to the cursor control mode.
13. A system comprising: a display;
a window to display window contents, the window having a field having a plurality of predetermined areas surrounded by a separate window frame, the separate window frame including a vertical scroll bar having a vertical scroll tab and a horizontal scroll bar having a horizontal scroll tab;
a cursor control mode, during which a user can move a cursor within a graphical user interface (GUI) in response to positional data received from a cursor control device controlled by the user, wherein the movement of the cursor within the GUI is directly based on the positional data and the cursor does not move when the there is no change in the received positional data;
a scroll control mode that is entered when the user performs a clicking action comprising a button press and a button release event with a button of the cursor control device when the cursor is positioned within one of the plurality of predetermined areas in the field, said plurality of predetermined areas including separate predetermined areas that are located proximate to the vertical scroll tab, proximate to the horizontal scroll tab, and elsewhere within the field, wherein a vertical scroll control mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area proximate to the vertical scroll tab, a horizontal scroll control mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area proximate to the horizontal scroll tab, and a panning scroll mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area located elsewhere within the field, wherein in the scroll control mode, scrolling of the contents of the window is directly based only on positional data received from the cursor control device in the direction of entered scroll control mode, and the contents of the window do not scroll when there is no change in the received positional data, whereby any time the positional data received from the cursor control device indicates no movement in the scroll control mode, the contents of the window do not scroll, and whereby if there is no horizontal change in the positional data received from the cursor control device when in horizontal scroll control mode, then the contents of the window do not scroll, and whereby if there is no vertical change in the positional data received from the cursor control device when in vertical scroll control mode, then the contents of the window do not scroll; and
an inactivity timeout interval comprising a threshold time period, that if elapsed without any activity received from the cursor control device including horizontal change or vertical change in the received positional data and clicking actions, causes the GUI to return to the cursor control mode from the scroll control mode in response to the lapsing of the inactivity timeout interval.
14. The system of claim 13, wherein the cursor control device comprises a mouse, and wherein the positional data received from the mouse corresponds with movements of the mouse, such that the mouse is not being moved when there is no change in the received positional data.
15. The system of claim 14, wherein the clicking action is performed using a primary button of the mouse.
16. The system of claim 15, wherein the primary button of the mouse is not dedicated to scrolling functionality.
17. The system of claim 13, wherein the cursor control device comprises a touch pad, and wherein the positional data received from the touch pad corresponds with movements of the user’s finger or stylus over the surface of the touch pad, such that the finger or stylus is not being moved when there is no change in the received positional data.
18. The system of claim 17, wherein the clicking action comprises a is performed using a primary button associated with the touch pad.
19. The system of claim 18, wherein the primary button associated with the touch pad is not dedicated to scrolling functionality.
20. The system of claim 13, wherein the cursor control device comprises a trackball or a joystick.
21. The system of claim 13, wherein the appearance of the scroll tab changes to indicate being in the scroll control when in scroll control mode.
22. The system of claim 13, wherein the user performing a second clicking action results in switching back to cursor control mode from scroll control mode.
23. The system of claim 13, wherein the elapsing of a threshold period of time without a change in the positional data results in switching back to cursor control mode from scroll control mode.
24. A removable program medium having stored thereon data representing instructions that, when executed by a processor, cause the processor to perform operations comprising:
operating a Graphical User Interface (GUI) that includes a window with a field having a plurality of predetermined areas surrounded by a separate window frame including a vertical scroll bar having a vertical scroll tab and a horizontal scroll bar having a horizontal scroll tab, in a cursor control mode, moving a cursor within the GUI in response to positional data received from a cursor control device, wherein the movement of the cursor within the GUI is directly based on the positional data and the cursor does not move when the there is no change in the received positional data;
receiving a clicking action from a button of the cursor control device in response to a user of the GUI clicking the button, the clicking action comprising a button press even and a button release event;
entering a scroll control mode in response to the received clicking action, in response to determining that the clicking action was received when the cursor was positioned within one of the plurality of predetermined areas in the field, said plurality of predetermined areas including separate predetermined areas that are located proximate to the vertical scroll tab, proximate to the horizontal scroll tab, and elsewhere within the field, wherein a vertical scroll control mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area proximate to the vertical scroll tab, a horizontal scroll control mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area proximate to the horizontal scroll tab, and a panning scroll mode is entered in response to determining that the clicking action was received when the cursor was positioned within a predetermined area located elsewhere within the field;
wherein in the scroll control mode, scrolling of the contents of the window is directly based only on positional data received from the cursor control device in the direction of entered scroll control mode, and the contents of the window do not scroll when there is no change in the received positional data, whereby any time the positional data received from the cursor control device indicates no movement in the scroll control mode, the contents of the window do not scroll, and whereby if there is no horizontal change in the positional data received from the cursor control device when in horizontal scroll control mode, then the contents of the window do not scroll, and whereby if there is no vertical change in the positional data received from the cursor control device when in vertical scroll control mode, then the contents of the window do not scroll;
determining that a time period of inactivity has elapsed during which there was no activity by the cursor control device, such that no horizontal change and no vertical change in the received positional data and no clicking actions are received from the cursor control device during the inactive time period; and
returning to the cursor control mode from the scroll control mode in response to the determination that the time period of inactivity has elapsed, wherein in the cursor control mode the movement of the cursor within the GUI is directly based on the positional data and the cursor does not move when the there is no change in the received positional data.
25. A removable program medium of claim 24, wherein the cursor control device comprises a mouse, and wherein the positional data received from the mouse corresponds with movements of the mouse, such that the mouse is not being moved when there is no change in the received positional data.
26. A removable program medium of claim 25, wherein the received clicking action is performed using a primary button of the mouse.
27. A removable program medium of claim 26, wherein the primary button of the mouse is not dedicated to scrolling functionality.
28. A removable program medium of claim 24, wherein the cursor control device comprises a touch pad, and wherein the positional data received from the touch pad corresponds with movements of a user’s finger or stylus over the surface of the touch pad, such that the finger or stylus is not being moved when there is no change in the received positional data.
29. A removable program medium of claim 28, wherein the received clicking action is performed using a primary button associated with the touch pad.
30. A removable program medium of claim 29, wherein the primary button associated with the touch pad is not dedicated to scrolling functionality.
31. A removable program medium of claim 24, wherein the cursor control device comprises a trackball or a joystick.
32. A removable program medium of claim 24, further comprising changing an appearance of the scroll tab to indicate being in the scroll control mode in response to entering the scroll control mode.
33. A removable program medium of claim 32, further comprising changing the appearance of the scroll tab to indicate no longer being in the scroll control mode in response to returning to the cursor control mode.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I:
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
A is selected from CO2H, CH2CO2H, \u2014CO2R6, \u2014CONHOH, and \u2014CONHOR5, \u2014CONHOR6;
ring B is a 5 membered non-aromatic carbocycle;
ring C forms a spiro ring on Ring B and is a 5 membered heterocycle comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and 1 ring heteroatoms selected from O, N, NR2, and S(O)p and substituted with 0-6 Re;
Z is phenyl substituted with 0-4Rb;
Ua is absent or is O;
Xa is absent or is C1-3 alkylene;
Ya is absent;
Za is substituted with 0-5 Rc and selected from the group: benzoimidazolyl, indolyl, benzothiazin-4-yl, 1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl,1,1-dioxido-3,4-dihydro-2H-1-benzothiopyran-4-yl, 3,4-dihydro-2H-chromen-4-yl, 2H-chromen-4-yl, and benzofuranyl;
R1 is selected from H, C1-4 alkyl, phenyl, and benzyl;
R2 is selected from Q, Cl, F, (C1-10 alkylene substituted with 0-3 Rb1)-Q, (C2-10 alkenylene substituted with 0-3 Rb1)-Q, (C2-10 alkynylene substituted with 0-3 Rb1)-Q, (CRaRa1)r1O(CRaRa1)r-Q, (CRaRa1)r1NRa(CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa1)r1C(O)O\u2014C2-5 alkenylene, (CRaRa1)r1C(O)O\u2014C2-5 alkynylene, (CRaRa1)r1OC(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)NRaRa1, (CRaRa1)r1C(O)NRa(CRaRa1 )r-Q, (CRaRa1)r1NRaC(O)(CRaRa1)r-Q, (CRaRa1)r1OC(O)O(CRaRa1)r-Q, (CRaRa1)r1OC(O)NRa(CRaRa1)r-Q, (CRaRa1)r1NRaC(O)O(CRaRa1)r-Q, (CRaRa1)r1NRaC(O)NRa(CRaRa1)r-Q, (CRaRa1)r1S(O)p(CRaRa1)r-Q, (CRaRa1)r1SO2NRa(CRaRa1)r1-Q, (CRaRa1)r1NRaSO2(CRaRa1)r-Q and (CRaRa1)r1NRaSO2NRa(CRaRa1)r-Q;
R2a is selected from H, C1-6 alkyl, ORa, NRaRa1, and S(O)pRa;
R2b is H or C1-6 alkyl;
Q is selected from H and a C3-13 carbocycle substituted with 0-5 Rd;
R3 is selected from Q1, Cl, F, C1-6 alkylene-Q1, C2-6 alkynylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, (CRaRa1)r1NRaC(O)(CRaRa1)r-Q1, (CRaRa1)r1C(O)NRa(CRaRa1)r-Q1, (CRaRa1)r1C(O)(CRaRa1)r-Q1, (CRaRa1)r1C(O)O(CRaRa1)r-Q1, (CRaRa12)r1S(O)p(CRaRa1)r-Q1, and (CRaRa1)r1SO2NRa(CRaRa1)r-Q1;
Q1 is selected from H, phenyl substituted with 0-3 Rd, and naphthyl substituted with 0-3 Rd;
Ra, at each occurrence, is independently selected from H, C1-4 alkyl, phenyl and benzyl;
Ra1, at each occurrence, is independently selected from H and C1-4 alkyl;
Ra2, at each occurrence, is independently selected from C1-4 alkyl, phenyl and benzyl;
Rb, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, \u2550O, \u2014CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, and CF2CF3;
Rb1, at each occurrence, is independently selected from ORa, Cl, F, Br, I, \u2550O, \u2014CN, NO2, and NRaRa1;
Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, \u2550O, \u2014CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, CF2CF3, CH2F, CHF2, CF2CH3, C(CH3)2F, OCF3, and C3-10 carbocycle substituted with 0-3 Rc1;
Rc1, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, \u2550O, \u2014CN, NO2, NRaRa1, C(O)Ra,C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, CF2CF3, CH2F, and CHF2;
Rd, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, \u2550O, \u2014CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, CF2CF3, and C3-10 carbocycle;
Re, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, \u2550O, \u2014CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, CF2CF3, C3-10 carbocycle substituted with 0-2 Rc1, and (CRaRa1)r1-C3-10 carbocycle substituted with 0-2 Rc1;
R5, at each occurrence, is selected from C1-10 alkyl substituted with 0-2 Rb, and C1-8 alkyl substituted with 0-2 Rf;
Rf, at each occurrence, is selected from phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb;
R6, at each occurrence, is selected from phenyl, naphthyl, C1-10 alkyl-phenyl-C1-6 alkyl-, C3-11 cycloalkyl, C1-6 alkylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxycarbonyloxy-C1-3 alkyl-, C2-10 alkoxycarbonyl, C3-6 cycloalkylcarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyloxy-C1-3 alkyl-, C3-6 cycloalkoxycarbonyl, phenoxycarbonyl, phenyloxycarbonyloxy-C1-3 alkyl-, phenylcarbonyloxy-C1-3 alkyl-, C1-6 alkoxy-C1-6 alkylcarbonyloxy-C1-3 alkyl-, 5-(C1-C5 alkyl)-1,3-dioxa-cyclopenten-2-one-ylmethyl, 5-(Ra)-1,3-dioxa-cyclopenten-2-one-ylmethyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, \u2014C1-10 alkyl-NR7R7a, \u2014CH(R8)OC(\u2550O)R9, and \u2014CH(R8)OC(\u2550O)OR9;
R7 is selected from H and C1-10 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-;
R7ais selected from H and C1-10 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-;
R8 is selected from H and C1-4 linear alkyl;
R9 is selected from H, C1-8 alkyl substituted with 1-2 Rg, C3-8 cycloalkyl substituted with 1-2 Rg, and phenyl substituted with 0-2 Rb;
Rg, at each occurrence, is selected from C1-4 alkyl, C3-8 cycloalkyl, C1-5 alkoxy, and phenyl substituted with 0-2 Rb;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,
r1, at each occurrence, is selected from 0, 1, 2, 3, and 4.
2. A compound according to claim 1, wherein the compound is of formula II:
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
Z is phenyl substituted with 0-3 Rb;
R2 is selected from Q, C1-6 alkylene-Q, C2-6 alkenylene-Q, C2-6 alkynylene-Q, (CRaRa1)r1O(CRaRa1)r-Q, (CRaRa1)r1NRa(CRaRa1)r-Q, (CRaRa1)r1C(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa1)rC(O)NRaRa1, (CRaRa1)r1C(O)NRa(CRaRa1)r-Q, (CRaRa1)r1S(O)p(CRaRa1)r-Q, and (CRaRa1)r1SO2NRa(CRaRa1)r-Q;
Q is selected from H, and a C3-6 carbocycle substituted with 0-5 Rd;
Rb, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, \u2550O, \u2014CN, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, and CF3;
Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, \u2550O, \u2014CN, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3, CH2FCHF2, CF2CH3, C(CH3)2F, OCF3, C3-6 carbocycle substituted with 0-2 Rc1;
Rc1, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, I, \u2550O, \u2014CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra2, NRaS(O)2NRaRa1, OS(O)2NRaRa1, NRaS(O)2Ra2, S(O)pRa2, CF3, CF2CF3, CH2F, and CHF2;
Rd, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, \u2550O, \u2014CN, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3, and C3-6 carbocycle;
R7 is selected from H and C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-;
R7ais selected from H and C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C1-3 alkyl-, and phenyl-C1-6 alkyl-;
R9 is selected from H, C1-6 alkyl substituted with 1-2 Rg, C3-6 cycloalkyl substituted with 1-2 Rg, and phenyl substituted with 0-2 Rb; and
Rg, at each occurrence, is selected from C1-4 alkyl, C3-6 cycloalkyl, C1-5 alkoxy, and phenyl substituted with 0-2 Rb.
3. A compound according to claim 2, wherein the compound is of formula IIIa or IIIb:
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
A is selected from \u2014CO2H, CH2CO2H, \u2014CONHOH, \u2014CONHOR5, \u2014N(OH)CHO, and \u2014N(OH)COR5;
R2 is selected from Q, C1-6 alkylene-Q, C2-6 alkenylene-Q, C2-6 alkynylene-Q, (CRaRa1)rC(O)(CRaRa1)r-Q, (CRaRa1)r1C(O)O(CRaRa1)r-Q, (CRaRa2)r1C(O)NRaRa1, (CRaRa2)r1C(O)NRa(CRaRa1)r-Q, and (CRaRa1)r1S(O)p(CRaRa1)r-Q;
Q is selected from H a C3-6 carbocycle substituted with 0-3 Rd;
Rb, at each occurrence, is independently selected from C1-4 alkyl, ORa, Cl, F, \u2550O, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, and CF3;
Rc, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, \u2550O, NRaRa1, C(O)Ra, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3, CH2F, CHF2, CF2CH3, C(CH3)2F, cyclopropyl, 1-methylcyclopropyl, and cyclobutyl;
Rd, at each occurrence, is independently selected from C1-6 alkyl, ORa, Cl, F, Br, \u2550O, NRaRa1, C(O)Ra, C(O)NRaRa1, S(O)2NRaRa1, S(O)pRa2, CF3, and phenyl;
R5, at each occurrence, is selected from C1-4 alkyl substituted with 0-2 Rb, and C1-4 alkyl substituted with 0-2 Rf;
s and s1 combine to total 2; and
s2 and s3 combine to total 3.
4. A compound according to claim 3, wherein the compound is of formula IVa or IVb:
or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
Xa is absent or is CH2 or CH2CH2;
Za is substituted with 0-3 Rc and selected from the group: benzimidazolyl, indolyl, 1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl, 1,1-dioxido-3,4-dihydro-2H-1-benzothiopyran-4-yl, 3,4-dihydro-2H-chromen-4-yl, 2H-chromen-4-yl;
R1 is selected from H, CH3, and CH2CH3;
R2 is selected from Q, C1-6 alkylene-Q, C2-6 alkynylene-Q, C(O)(CRaRa1)r-Q, C(O)O(CRaRa1)r-Q, C(O)NRa(CRaRa1)r-Q, and S(O)p(CRaRa1)r-Q;
Q is selected from H, cyclopropyl substituted with 0-1 Rd, cyclobutyl substituted with 0-1 Rd, cyclopentyl substituted with 0-1 Rd, cyclohexyl substituted with 0-1 Rd, and phenyl substituted with 0-2 Rd ;
Ra, at each occurrence, is independently selected from H, CH3, and CH2CH3;
Ra1, at each occurrence, is independently selected from H, CH3, and CH2CH3;
Ra2, at each occurrence, is independently selected from H, CH3, and CH2CH3;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3;
r1, at each occurrence, is selected from 0, 1, 2, and 3;
s and s1 combine to total 2; and
s2 and s3 combine to total 3.
5. A compound according to claim 4, wherein the compound is of formula IVa or IVb, wherein;
Z is phenyl;
Za is substituted with 0-2 Rc and for the group: 1H-benzimidazol-1-yl, 1H-indol-1-yl, 1H-indol-3-yl, and 1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl;
R1 is H;
Rc, at each occurrence, is independently selected from methyl, ethyl, propyl, isopropyl, butyl, t-butyl, CF3, CHF2, CH2F, CF2CH3, C(CH3)2F, NH2, NH(CH3), N(CH3)2, cyclopropyl, 1-methylcyclopropyl, and cyclobutyl.
6. A compound according to claim 1, wherein the compound is selected from the group:
(5R,7S,8R)-N-hydroxy-8-({4-(2-methyl-1H-benzimidazol-1-yl)methylbenzoyl}amino)-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-N-hydroxy-8-({4-(2-isopropyl-1H-benzimidazol-1-yl)methylbenzoyl}amino)-1-oxaspiro4.4nonane-7carboxamide;
(5R,7S,8R)-N-hydroxy-8-(4-{2-(trifluoromethyl-1H-benzimidazol-1-ylmethyl}benzoyl)amino-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7R,8-({4-(2-tert-butyl-1H-benzimidazol-1-yl)methyl-benzyl}amino)-N-hydroxy-1-oxaspiro4.4nonane-7carboxamide;
(5R,7S,8R)-N-hydroxy-8-({4-(2-methyl-1H-indol-3yl)methylbenzoyl}amino)1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-(4-{(2-difluoromethyl)-1H-benzimidazol-1-ylmethyl}benzoyl)amino-N-hydroxy-1-oxaspiro4.4nonane-7carboamide;
(5R,7S,8R)-8-({4-(2-cyclopropyl-1H-benzimidazol-1-yl)methylbenzoyl}amino)-N-hydroxy-1-oxaspiro4.4nonane-7-carboamide;
(5R,7S,8R)-8-({4-(2-cyclobutyl-1H-benzimidazol-1-yl)methylbenzoyl}amino)-N-hydroxy-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-N-hydroxy-8-({4-(2-methyl-1H-indol-1-yl)methylbenzoyl}amino)-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-N-hydroxy-8-(4-{2-(1-methylcyclopropyl)-1H-benzimidazol-1-ylmethyl}benzoyl)amino-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-(4-{2-(fluoromethyl)-1H-benzimidazol-1ylmethyl}benzoyl)amino-N-hydroxy-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-(4-{2-(1-fluoro-1-methylethyl)-1H-benzimidazol-1-ylmethyl}benzoyl)amino-N-hydroxy-1-oxaspiro4.4nonane-7carboxamide;
(5R,7S,8R)-N-hydroxy-8-{4-(1H-indol-3-ylmethyl)benzoylamino}-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-(4-{(2-(1,1-difluoroethyl)-1H-benzimidazol-1-ylmethyl}benzoyl)amino-N-hydroxy-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-({4-(2,3-dimethyl-1H-indol-1-yl)methylbenzoyl}amino)-N-hydroxy-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-N-hydroxy-8-(4-{2-(trifluoromethyl)-1H-indol-1-ylmethyl}benzoyl)amino-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-{(4-(1,1-dioxido-3,4-dihydro-2H-1benzothiopyran-4-yl)benzoylamino}-N-hydroxy-1oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-{4-(3,4-dihydro-2H-chromen-4yl)benzoylamino}-N-hydroxy-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-{4-(2H-chromen-4-yl)benzoylamino}-N-hydroxy-1-oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-({4-(1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl)methylbenzoyl}amino)-N-hydroxy-1oxaspiro4.4nonane-7-carboxamide;
(5R,7S,8R)-8-({4-(2,2-dimethyl-1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl)methylbenzoyl}amino)-N-hydroxy-1-oxaspiro4.4nonane-7-carboxamide;
or a pharmaceutically acceptable salt from thereof.
7. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt form thereof.
8. A method of treating an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt form thereof.
9. A method of treating a disease or condition by administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt form thereof, wherein the disease or condition is selected from Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and spondylitis.
10. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt form thereof.
11. A method of treating an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 or a pharmaceutically acceptable salt form thereof.
12. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt form thereof.
13. A method of treating an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 3 or a pharmaceutically acceptable salt form thereof.
14. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 4 or a pharmaceutically acceptable salt form thereof.
15. A method of treating an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 4 or a pharmaceutically acceptable salt form thereof.
16. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt form thereof.
17. A method of treating an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 5 or a pharmaceutically acceptable salt form thereof.
18. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 6 or a pharmaceutically acceptable salt form thereof.
19. A method of treating an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 6 or a pharmaceutically acceptable salt form thereof.